...
首页> 外文期刊>Macromolecular bioscience >A Core Cross-Linked Polymeric Micellar Platium(IV) Prodrug with Enhanced Anticancer Efficiency
【24h】

A Core Cross-Linked Polymeric Micellar Platium(IV) Prodrug with Enhanced Anticancer Efficiency

机译:具有增强的抗癌效率的核心交联聚合物胶束铂(IV)前药

获取原文
获取原文并翻译 | 示例

摘要

A core cross-linked polymeric micellar cisplatin(IV) conjugate prodrug is prepared by attaching the cisplatin(IV) to mPEG-b-PLL biodegradable copolymers to form micellar nanoparticles that can disintegrate to release the active anticancer agent cisplatin(II) in a mild reducing environment. Moreover, in vitro studies show that this cisplatin(IV) conjugate prodrug displays enhanced cytotoxicity against HepG2 cancer cells compared with cisplatin(II). Further studies demonstrate that the high cellular uptake and platinum-DNA adduct of this cisplatin(IV) conjugate prodrug can induce more cancer-cell apoptosis than cisplatin(II), which is responsible for its enhanced anticancer activity.
机译:通过将顺铂(IV)连接到mPEG-b-PLL可生物降解的共聚物上形成胶束纳米颗粒,可以形成核交联的聚合物胶束顺铂(IV)共轭前药,该纳米颗粒可以分解并在温和的条件下释放出活性抗癌剂顺铂(II)。减少环境。此外,体外研究表明,与顺铂(II)相比,这种顺铂(IV)共轭前药显示出增强的针对HepG2癌细胞的细胞毒性。进一步的研究表明,这种顺铂(IV)结合物前药的高细胞摄取和铂-DNA加合物比顺铂(II)可以诱导更多的癌细胞凋亡,这是顺铂(II)增强抗癌活性的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号